FULGENT GENETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.1 USD | +0.35% |
|
-1.28% | -30.47% |
| 03-06 | Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating | MT |
| 02-29 | UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating | MT |
Chart calendar Fulgent Genetics, Inc.
a6ab463076d.Kic2hWFoAahAex-mdsaX9ik8N0gforMYaIVhRjWLOJ0.X2tY8jIYa8ISD3ySW6ntgx5zBCxtwNxSHOMvfw3aTehPE1XcVAMxxzkVLw~156e1f35aa08455d70655c2d749dd8eb
Upcoming events on Fulgent Genetics, Inc.
Past events on Fulgent Genetics, Inc.
| 28/02/2024 13:30 | Q4 2023 Earnings Call |
| 28/02/2024 12:00 | Q4 2023 Earnings Release |
| 28/11/2023 17:00 | Piper Sandler Healthcare Conference |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract No - 782-B |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract No - 222-B |
| 03/11/2023 12:30 | Q3 2023 Earnings Call |
| 03/11/2023 11:00 | Q3 2023 Earnings Release |
| 04/08/2023 13:30 | Q2 2023 Earnings Call |
| 04/08/2023 12:00 | Q2 2023 Earnings Release |
| 03/06/2023 14:00 | American Society of Clinical Oncology Conference - Abstract #3026 |
| 18/05/2023 17:00 | Annual General Meeting |
| 05/05/2023 13:30 | Q1 2023 Earnings Call |
| 05/05/2023 12:00 | Q1 2023 Earnings Release |
| 07/03/2023 13:05 | Raymond James Institutional Investors Conference |
| 28/02/2023 21:30 | Q4 2022 Earnings Call |
| 28/02/2023 21:05 | Q4 2022 Earnings Release |
| 30/11/2022 15:00 | Piper Sandler Healthcare Conference |
| 08/11/2022 16:00 | Credit Suisse Healthcare Conference |
| 07/11/2022 21:30 | Q3 2022 Earnings Call |
| 07/11/2022 21:05 | Q3 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 32,5 32,6 -0.37% | 422 326 29.28% | 993 932 6.5% | 619 611 1.34% | 289 285 1.47% | 279 |
|
EBITDA Million USD | Released Forecast Spread | 4,85 4,45 9.13% | 301 192 56.86% | 704 636 10.6% | 257 260 -1.09% | 1,50 6,35 -76.31% | -25,9 |
|
EBIT Million USD | Released Forecast Spread | -0,43 1,53 -127.95% | 290 193 50.48% | 676 633 6.78% | 179 183 -2.41% | -196 -51,5 -279.65% | -83,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,41 2,14 -80.87% | 292 190 53.29% | 677 632 7.25% | 184 185 -0.76% | -174 -50,9 -242.06% | -86,9 |
|
Net income Million USD | Released Forecast Spread | -0,41 0,30 -239.32% | 214 146 46.69% | 507 482 5.2% | 143 159 -10.03% | -168 -59,9 -180.18% | -69,3 |
|
EPS USD | Released Forecast Spread | -0,02 0,01 -300% | 8,91 6,28 41.88% | 16,4 15,7 4.44% | 4,63 4,39 5.47% | -5,63 -2,05 -174.63% | -2,31 |
| Announcement Date | 10/03/20 | 04/03/21 | 23/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 252 191 31.7% | 320 271 18.25% | 125 123 2.15% | 106 91,4 15.65% | 67,7 59,6 13.65% | 66,2 60,1 10.19% | 67,9 62,5 8.6% | 84,7 64,4 31.46% | 70,5 66,3 6.31% | 65,4 | 69,1 | 71,1 | 73,9 | 75,9 |
|
EBITDA Million USD | Released Forecast Spread | 160 106 50.23% | 213 140 52.46% | 31,1 40,0 -22.37% | 10,2 15,5 -34.37% | -15,1 -10,9 -38.57% | -7,17 -16,3 56.11% | -2,71 -11,6 76.63% | 18,1 -6,96 360.72% | -6,76 -2,97 -127.66% | -9,24 | -6,78 | -3,71 | -6,22 | -5,68 |
|
EBIT Million USD | Released Forecast Spread | 151 108 40.04% | 202 158 27.6% | 12,8 24,0 -46.69% | 0,35 0,00 - | -36,6 -32,1 -13.85% | -24,8 -34,5 28% | -19,8 -29,5 32.88% | 0,21 -26,6 100.8% | -151 -19,4 -680.76% | -22,3 | -20,9 | -19,3 | -20,9 | -20,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 151 105 43.99% | 202 138 46.36% | 13,8 24,0 -42.7% | 1,76 -1,61 208.96% | -33,5 -28,9 -15.92% | -21,0 -31,9 33.91% | -14,7 -27,2 46.03% | 6,86 -24,2 128.33% | -145 -21,9 -561.55% | -22,9 | -21,5 | -19,6 | -22,4 | -20,6 |
|
Net income Million USD | Released Forecast Spread | 104 79,2 31.69% | 154 116 32.4% | 11,5 18,0 -35.91% | 1,72 -0,99 273.64% | -23,8 -19,5 -21.91% | -15,3 -23,2 33.9% | -11,2 -19,6 42.57% | -13,1 -19,2 31.8% | -128 -19,4 -558.95% | -18,2 | -17,4 | -16,0 | -17,7 | -16,1 |
|
EPS USD | Released Forecast Spread | 3,34 2,61 28.13% | 4,93 3,86 27.72% | 0,06 -0,06 200% | -0,80 -0,75 -6.67% | -0,52 -0,67 22.39% | -0,38 -0,66 42.42% | -0,44 -0,61 27.87% | -4,30 -0,72 -497.22% | -0,62 | -0,58 | -0,53 | -0,59 | -0,53 | |
| Announcement Date | 23/02/22 | 03/05/22 | 04/08/22 | 07/11/22 | 28/02/23 | 05/05/23 | 04/08/23 | 03/11/23 | 28/02/24 | - | - | - | - | - |
| 28/04/2024 | SMO CLINPLUS CO.,LTD.: Q4 2023 Earnings Release |
| 29/04/2024 | NEOGENOMICS, INC.: Q1 2024 Earnings Release |
| 03/05/2024 12:00 | FULGENT GENETICS, INC.: Q1 2024 Earnings Release |
| 05/05/2024 | OPKO HEALTH, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | RADNET, INC.: Q1 2024 Earnings Release |
| 07/05/2024 | SYNLAB AG: Q1 2024 Earnings Release |
| 08/05/2024 | FLEURY S.A.: Q1 2024 Earnings Release |
| 09/05/2024 | H.U. GROUP HOLDINGS, INC.: Q4 2023 Earnings Release |
| 09/05/2024 | BML, INC.: Q4 2023 Earnings Release |
| 09/05/2024 | GC CELL CORPORATION: Q1 2024 Earnings Release (Projected) |
Past sector events for Fulgent Genetics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- FLGT Stock
- Calendar Fulgent Genetics, Inc.
